Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
| Condition | Epileptic Encephalopathy, Continuous Spike and Wave During Sleep |
|---|---|
| Phase | Phase 2 |
| Sponsor | Neurocrine Biosciences |
| Status | Terminated |
| Enrollment | 19 participants |
| Interventions | NBI-827104 |
| Start date | Jun 7, 2022 |
| Completion date | Jan 27, 2025 |
| Results posted | Feb 13, 2026 |
Summary
The primary objective for this study is to evaluate the long-term safety and tolerability of NBI-827104 in pediatric participants with epileptic encephalopathy with continuous spike-and-wave during sleep (EECSWS).
The Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs)
| NBI-827104 | 2 Participants |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Safety and Efficacy of tPBM for Epileptiform Activity in Autism — Richard Frye
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
- Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines — Rutgers, The State University of New Jersey
- Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
- A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
- Maintenance TMS in Treatment Resistant Depression — Austin Messner